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Objective: Cardiopulmonary bypass has been shown to exert an inflammatory response within the lung, often
resulting in postoperative pulmonary dysfunction. Several studies have shown that adenosine A2A receptor acti-
vation attenuates lung ischemia-reperfusion injury; however, the effect of adenosine A2A receptor activation on
cardiopulmonary bypass-induced lung injury has not been studied. We hypothesized that specific adenosine A2A
receptor activation by ATL313 would attenuate inflammatory lung injury after cardiopulmonary bypass.
Methods: Adult male Sprague-Dawley rats were randomly divided into 3 groups: 1) SHAM group (underwent
cannulationþheparinization only); 2) CONTROL group (underwent 90 minutes of normothermic cardiopulmo-
nary bypass with normal whole-blood priming solution; and 3) ATL group (underwent 90 minutes of normother-
mic cardiopulmonary bypass with ATL313 added to the normal priming solution).
Results: There was significantly less pulmonary edema and lung injury in the ATL group compared with the
CONTROL group. The ATL group had significant reductions in bronchoalveolar lavage interleukin-1, interleu-
kin-6, interferon-g, and myeloperoxidase levels compared with the CONTROL group. Similarly, lung tissue in-
terleukin-6, tumor necrosis factor-a, and interferon-g were significantly decreased in the ATL group compared
with the CONTROL group. There was no significant difference between the SHAM and ATL groups in the
amount of pulmonary edema, lung injury, or levels of proinflammatory cytokines.
Conclusion: The addition of a potent adenosine A2A receptor agonist to the normal priming solution before the
initiation of cardiopulmonary bypass significantly protects the lung from the inflammatory effects of cardiopul-
monary bypass and reduces the amount of lung injury. Adenosine A2A receptor agonists could represent a new
therapeutic strategy for reducing the potentially devastating consequences of the inflammatory response associ-
ated with cardiopulmonary bypass.Since its successful introduction by Dr Gibbon in 1953,1
cardiopulmonary bypass (CPB) has seen substantial evolu-
tion. Despite this, ample evidence exists regarding the
massive inflammatory response that is initiated after proce-
dures that use CPB.2-5 The majority of patients undergoing
CPB have sufficient reserve to overcome this inflammatory
insult without clinically observable sequelae. In a smaller
cohort of patients, however, this inflammatory response
can result in system-wide organ dysfunction leading to
respiratory failure, renal insufficiency and failure, coagulo-
pathies, neurologic dysfunction, altered hepatic function,
and, in an even smaller number of patients, acute respira-
tory distress syndrome and systemic inflammatory
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triggered is thought to occur from a highly sensitive set
of interactions between the normal circulation and the
‘‘foreign’’ surface of the CPB circuit, which results in
an incremental activation of complement, coagulation, fi-
brinolytic, and inflammatory responses.4 In addition,
some argue that end-organ ischemia and the subsequent re-
perfusion injury that results is another powerful player in
this inflammatory response.2 The ability to reconcile this
pathologic and potentially lethal process relies on the abil-
ity to attenuate the unyielding inflammatory response that
is characteristic of CPB.
The role of adenosine in limiting the inflammatory re-
sponse to CPB is a logical continuation of the success that
has been described with adenosine agonists and their wide-
spread effects on ischemia-reperfusion injury in multiple dif-
ferent organ systems.6-9 The adenosine A2A receptor (A2AR)
is 1 of 4 G-protein coupled receptors that belong to the aden-
osine receptor family (A1, A2A, A2B, A3). The A2AR is ex-
pressed predominantly on inflammatory cells, including
neutrophils, macrophages, mast cells, monocytes, and plate-
lets. Once activated, this G-protein coupled receptor leads to
an increase in intracellular cyclic adenosine monophosphate,
which results in a potent inactivation of inflammatory cells,
decreased proinflammatory cytokine production and release,
suppressed neutrophil recruitment and activation, decreasedurgery c November 2008
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PAbbreviations and Acronyms
A2AR ¼ adenosine A2A receptor
BAL ¼ bronchoalveolar lavage
CPB ¼ cardiopulmonary bypass
IFN ¼ interferon
IL ¼ interleukin
MPO ¼ myeloperoxidase
TNF ¼ tumor necrosis factor
oxygen free radical production, and possibly down-regula-
tion of cellular immunity through impaired CD4þT-cell ac-
tivity.10,11
In this study, we examined the effect of A2AR activation
on the inflammatory response within the lung caused by
CPB by adding the highly selective A2AR agonist,
ATL313 [4-{3-[6-amino-9-(5-cyclopropylcarbamoyl-3,4-
dihydroxytetrahydrofuran-2-yl)-9H-purin-2-yl]prop-2-ynyl}
piperidine-1-carboxylic acid methyl ester], to the standard
bypass priming solution before the initiation of CPB.
Previous research has demonstrated that specific activa-
tion of the A2AR subtype has been shown to have significant
anti-inflammatory effects.6,9 Furthermore, our institutional
research has shown that the specific activation of the
A2AR is mediated by ATL313.
6 We therefore hypothesized
that activation of the A2AR in the standard bypass prime be-
fore the start of CPB would lead to an attenuation in the pul-
monary inflammatory response observed after CPB.
MATERIALS AND METHODS
Animals and Groups
Adult male Sprague-Dawley rats (Charles River Laboratories, Wilming-
ton, Mass) (350–450 g) were used for all studies and received humane care
in accordance with the ‘‘Guide for the Care and Use of Laboratory Ani-
mals’’ published by the National Institutes of Health (NIH publication
No. 85-23, revised 1996). The Animal Care and Use Committee at the Uni-
versity of Virginia reviewed and approved the protocol for this study before
experimentation began.
Rats were randomly assigned to 1 of 3 groups (n ¼ 5 for each group):
SHAM group, CPBwith normal whole blood priming solution (CONTROL
group), and CPB with normal whole blood priming solution plus ATL313
(ATL group). The sham operation consisted of all venous and arterial can-
nulations, as well as full heparinization without CPB.
Surgical Procedure
The rat model of CPB was based on the model for extracorporeal circu-
lation in the rat as developed by Grocott and associates.12 Rats were anes-
thetized with 4% isoflurane. After adequate anesthesia was achieved, rats
were intubated by direct laryngoscopy with a 14-gauge intravenous catheter
(BD Insyte Autoguard, Becton-Dickinson Infusion Therapy Systems Inc,
Sandy, Utah) and mechanically ventilated by a small-animal ventilator
(TOPO Dual Mode Ventilator, Kent Scientific, Torrington, Conn) with
an air-oxygen mixture (FIO2 ¼ 0.5). During the cannulations, ventilation
was adjusted to maintain a partial pressure of carbon dioxide (PaCO2) be-
tween 35 and 42 mm Hg. During the surgical procedure, anesthesia was
maintained with 2% to 2.5% isoflurane and adjusted as appropriate toThe Journal of Thoracic and Cachieve adequate depth of anesthesia. All surgeries were performed with
standard sterile techniques. The surgical cannulations and CPB circuit are
illustrated in Figure 1. Rectal temperature was monitored and regulated
at 37.3C to 37.6C using a combination of heat lamps, 2 forced water-
heating blankets, and a forced air-warming blanket as needed. Electrocardi-
ography and pulse oximetry were continuously monitored using a small
animal portable monitoring system (SurgiVet V3404 Plus, SurgiVet Inc,
Waukesha, Wis).
The tail artery was identified through a 1-cm ventral tail incision, en-
circled with 5-0 silk sutures, and cannulated with a modified 22-gauge in-
travenous catheter (BD Insyte, Becton-Dickinson Infusion Therapy
Systems Inc) to serve as the arterial inflow cannula. After this, the femoral
artery was identified through a 1-cm right groin incision and encircled with
5-0 silk sutures. A 24-gauge intravenous catheter (BD Insyte, Becton-Dick-
inson Infusion Therapy Systems Inc) was then inserted for continuous mean
arterial pressure monitoring and intermittent arterial blood gas analysis
(Rapidpoint 405 series, Bayer HealthCare LLC, Tarrytown, NY). Next,
through a 2-cm midline cervical incision, the right internal jugular vein
was identified and encircled with 5-0 silk sutures. A modified 8F multi-or-
ifice pediatric femoral venous cannula (Biomedicus 96830-008, Medtronic
Inc, Minneapolis, Minn) was inserted into the vein and gently advanced into
the right atrium. The position of the venous cannula was confirmed by pre-
vious autopsy studies and allowed for complete drainage of the right atrium,
bilateral superior vena cava, and inferior vena cava. On insertion of the ve-
nous cannula, 200 IU of unfractionated heparin were given directly via the
venous cannula, allowing for an activated clotting time 450 seconds or
more.
Cardiopulmonary Bypass Circuit and Procedure
The CPB circuit (Figure 1) consisted of a sterile 5-mL venous reser-
voir (Bubble Trap Compliance Chamber, Radnoti Glass Technology Inc,
Monrovia, Calif). The venous reservoir was connected to a peristaltic
FIGURE 1. Schematic diagram of the rat CPB circuit and surgical cannu-
lations. Ventilator not shown. MAP, Mean arterial pressure.ardiovascular Surgery c Volume 136, Number 5 1281
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Proller-pump (Masterflex, Cole-Parmer Instrument Company, Chicago,
Ill) through sterile 1.6-mm internal diameter silicone tubing (Tygon,
Cole-Parmer Instrument Company) connected in series to a custom
flow probe (Transonic Flowprobe, Transonic Systems Inc, Ithaca NY)
used to continuously monitor blood flow rates during CPB. Additional
sterile 1.6-mm internal diameter silicone tubing was used to connect
the flow probe to an externally warmed sterile hollow-fiber membrane
oxygenator (MiniModule, Membrana, Charlotte, NC) with an active sur-
face area of 0.18 m2. The oxygenator was inverted to serve an additional
role as an inline arterial bubble trap and then connected to additional
sterile 1.6-mm internal diameter silicone tubing, surrounded by a jacket
warmed with circulating water from a separate heat pump, and then to
the previously mentioned arterial inflow cannula. Venous drainage was
augmented as needed by either adjusting the placement of the venous
cannula or changing the height of the venous reservoir relative to the an-
imal to increase or decrease gravity drainage of the right atrium and its
associated structures.
The CPB circuit was primed with 45 mL of whole blood obtained from 2
to 3 heparinized (250 IU/kg) donor rats phlebotomized under isoflurane an-
esthesia via direct cardiac puncture. For the ATL group, ATL313 (Adeno-
sine Therapeutics LLC, Charlottesville, Va) was added directly to the
whole blood prime at a dosage based on previous studies from our labora-
tory.6 From a 4.6 mmol/L stock solution of ATL313 in normal saline, 1
mLwas added to 45mL ofwhole blood and gentlymixed before pump prim-
ing. This resulted in a final dosage concentration of 100 nmol/L. For the
CONTROL group, an equivalent volume (1 mL) of vehicle (normal saline)
was injected into the 45 mL of whole blood before priming the CPB circuit.
After the surgical cannulations, heparinization, and adequate pump priming,
the animal was connected to the CPB circuit and extracorporeal circulation
was slowly initiated to a final flow rate of 160 to 165 mL/kg/min, which cor-
responds to 100% of the normal cardiac output in a rat. Once this flow rate
was attained, mechanical ventilation was terminated and CPB was carried
out for 90 minutes. During CPB, the gas flow to the oxygenator consisted
of oxygen, carbon dioxide, and isoflurane. At the conclusion of the 90-min-
ute period, mechanical ventilationwas resumed, and all animals were slowly
weaned fromCPBwithout the need for inotropes or vasopressors. Once sep-
arated from CPB, the rats were decannulated and remained intubated, anes-
thetized, and mechanically ventilated for an additional 90 minutes.
Physiologic Data and Specimen Collection
Blood pressure, mean arterial pressure, central venous pressure, heart
rate, pulse oximetry, temperature, and flow rate were monitored continu-
ously during the bypass period and recorded at baseline and 10, 20, 45,
60, and 90 minutes during the bypass procedure. The same variables (ex-
cluding flow rate) were monitored after the cessation of CPB and re-
corded at 30, 60, and 90-minute intervals. In addition, arterial blood
gas analysis was performed at the same prespecified intervals. At the
completion of the 90-minute recovery period, the chest was opened and
the rat was phlebotomized by direct cardiac puncture. Plasma was col-
lected by centrifugation at 4C for 20 minutes and stored at70C until
cytokine analysis was performed. The left lung was then isolated and re-
moved for subsequent tissue cytokine and wet-to-dry weight ratio analy-
sis. Next, a tracheostomy was performed followed by bronchoalveolar
lavage (BAL) of the entire right lung. After BAL was performed, the right
lung was removed and fixed by intratracheal instillation of 4% parafor-
maldehyde at 25 cm H2O pressure.
Lung Wet/Dry Weight Ratio
Lung wet/dry weight ratio was used as a measure of pulmonary
edema. Samples of the left lower lobe lung tissue were blotted to remove
excess blood and weighed immediately after harvest. These samples were
then desiccated under vacuum at 55C until a stable dry weight was
achieved.1282 The Journal of Thoracic and Cardiovascular SBronchoalveolar Lavage
BAL was performed on all lungs before en bloc removal and permanent
fixation. The right lung was isolated and lavaged 3 times with separate 10-
mL aliquots of normal saline. The BAL fluid was centrifuged at 1500g for
10 minutes at 4C. The supernatant was then snap-frozen for subsequent
analysis.
Myeloperoxidase Content
Myeloperoxidase (MPO) content in BAL fluid was measured using an
MPO enzyme-linked immunosorbent assay kit (Cell Sciences, Canton,
Mass) and performed according to the manufacturer’s instructions. MPO
content was used as a broad measure of neutrophil activation and sequestra-
tion.
Cytokine Analysis
The protein levels of tumor necrosis factor (TNF)-a, interleukin (IL)-1,
IL-6, and interferon (IFN)-g in lung tissue, plasma, and BAL fluid were ex-
amined with a Bio-Plex multiplex cytokine enzyme-linked immunosorbent
assay system (Bio-Rad Laboratories Inc, Hercules, Calif) and performed ac-
cording to the manufacturer’s instructions. Samples were run in triplicate.
Lung Injury Severity Score
A pathologist, blinded to treatment group, graded each lung sample after
appropriate tissue processing and staining (hematoxylin-eosin). Each sam-
ple was graded on the presence of the number of macrophages, amount of
interstitial infiltrate, and presence of alveolar edema. Each of these 3 cate-
gories was given a score of 0 to 3, resulting in a possible score ranging
from 0 for uninjured, normal lungs to 9 for the most severely injured lungs.
Statistics
Values are expressed as the mean standard error. All statistical analysis
was performed by an independent statistician. Analysis of variance and the
post hoc Bonferroni test were used to determine whether significant differ-
ences existed among the groups.
RESULTS
Physiologic and Arterial Blood Gas Measurements
Physiologic data are detailed in Table 1. The data were
similar for all 3 groups at both the baseline and the post-
bypass time points. The addition of ATL313 to the bypass
prime did not change any of the physiologic parameters
measured when comparing the CONTROL group with
the ATL group. Among the 3 groups, there were no signif-
icant differences noted in temperature, arterial oxygen sat-
uration, or hematocrit at any of the time points captured. In
the CONTROL and ATL groups, mean arterial pressure
decreased significantly while on CPB compared with
SHAM (P< .05 for all time points). There were no differ-
ences noted between the CONTROL group and the ATL
group in terms of CPB flow rates, with each at or slightly
above the projected goal flow rate of 160 to 165 mL/kg/
min.
In regard to arterial blood gas analysis (Table 2), there
were no differences noted between the CONTROL group
and the ATL group for pH, PaO2, PaCO2, or HCO3 at any
point during the experiment. When comparing the SHAM
group with the CONTROL and ATL groups, the SHAM
group was noted to have a higher pH and a slightly lowerurgery c November 2008
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CPB Post-CPB
Baseline 10 min 20 min 45 min 60 min 90 min 30 min 60 min 90 min
MAP (mm Hg)
SHAM 92  3.6 90  2.0a 92  1.6a 89  1.6a 84  1.5a 85  0.9a 89  3.5 91  3.0 90  1.1
CONTROL 89  8.9 75  5.6 73  4.5 72  4.4 75  4.1 71  6.3 80  4.5 85  4.1 88  2.8
ATL 88  3.8 76  3.9 72  5.1 76  3.8 75  4.1 72  4.1 82  3.0 86  4.6 86  4.4
CPB flow (mL/kg/min)
SHAM - - - - - - - - -
CONTROL - 161  0.3 164  1.1 160  0.7 165  1.2 162  2.3 - - -
ATL - 162  0.1 161  0.9 163  1.2 161  1.7 164  1.7 - - -
HCT (%)
SHAM 37  0.5 - 36  0.7 - 36  1.1 - - 36  0.4 -
CONTROL 39  1.4 37  0.6 37  0.6 38  0.3 38  0.6 37  1.6 38  0.9 37  1.3 38  1.1
ATL 37  0.6 36  0.5 37  0.9 37  0.6 38  0.7 38  0.2 39  0.7 39  0.6 39  0.5
Temperature (C)
SHAM 37.7  .04 37.6  .07 37.5  .11 37.4  .05 37.5  .03 37.4  .06 37.6  .06 37.5  .07 37.6  .06
CONTROL 37.5  .12 36.4  .09 36.9  .07 37.4  .15 37.4  .07 37.4  .04 37.4  .09 37.5  .08 37.5  .11
ATL 37.4  .16 36.7  .12 37.0  .08 37.4  .04 37.6  .06 37.5  .08 37.5  .08 37.6  .06 37.4  .07
SAO2 (%)
SHAM 98  0.5 99  1.1 99  1.0 99  0.3 98  0.6 98  0.5 97  0.4 99  0.7 98  0.2
CONTROL 98  0.4 99  0.7 99  0.7 98  0.5 98  0.6 99  0.7 98  0.6 97  0.9 97  0.2
ATL 99  0.2 98  0.6 98  0.9 99  0.7 99  0.7 98  0.7 99  0.3 98  0.3 98  0.5
MAP, Mean arterial pressure; CPB, cardiopulmonary bypass; HCT, hematocrit; SAO2, arterial oxygen saturation. Values represent mean  standard error. SHAM (n ¼ 5), CON-
TROL (n ¼ 5), ATL (n ¼ 5). aP< .05 versus CONTROL and ATL.C
S
PPaO2 at the 20- and 60-minute time points (P< .001). The
SHAM group was noted to have a slightly lower baseline
PaCO2 and HCO3 when compared with the CONTROL and
ATL groups (P< .05).
Cytokine Analysis
Enzyme-linked immunosorbent assay was used to deter-
mine whether the addition of ATL313 had any effect onThe Journal of Thoracic and Cathe quantity of proinflammatory cytokines in the lung tissue,
BAL fluid, or plasma (Table 3). Within lung tissue, CON-
TROL animals were found to have marked elevations in
IL-1, IL-6, TNF-a, and IFN-g after the 90-minute recovery
period compared with SHAM. In the ATL group, tissue ex-
pression of IL-6, TNF-a, and IFN-gwere significantly atten-
uated. Similar results were observed within the BAL fluid.
The CONTROL group was found to have significantTABLE 2. Arterial blood gas analysis
CPB Post-CPB
Baseline 10 min 20 min 45 min 60 min 90 min 30 min 60 min 90 min
pH
SHAM 7.42  .01 - 7.42  .01a - 7.45  .01a - - 7.45  .01a -
CONTROL 7.42  .02 7.39  .02 7.37  .01 7.39  .02 7.39  .02 7.38  .01 7.41  .01 7.38  .01 7.39  .01
ATL 7.39  .02 7.36  .03 7.36  .04 7.37  .03 7.38  .03 7.39  .03 7.38  .02 7.39  .01 7.38  .01
PaO2 (mm Hg)
SHAM 283  11 - 266  30a - 222  13a - - 298  33 -
CONTROL 289  20 371  53 379  46 392  53 392  49 325  58 297  31 259  24 244  15
ATL 298  34 383  38 400  30 369  41 377  46 381  19 312  30 251  11 293  12
PaCO2 (mm Hg)
SHAM 36  3b - 37  2 - 38  3 - - 38  2 -
CONTROL 41  4 39  1 40  1 38  2 37  3 41  2 41  2 39  2 39  .4
ATL 42  2 38  2 37  3 40  2 39  1 43  1 42  1 42  1 39  1
HCO3 (mEq)
SHAM 24.4  1.5b - 23.9  .75 - 23.8  .63 - - 25.1  .94 -
CONTROL 26.5  1.4 24.9  1.4 23.1  1.2 23.2  1.2 22.9  1.1 23.1  1.1 23.6  1.7 24.6  2.5 23.9  1.9
ATL 26.1  .46 25.1  .37 24.2  .43 24.1  .75 23.5  .81 23.7  .87 23.8  .83 24.3  .61 24.1  .44
PaO2, Partial pressure of oxygen; PaCO2, partial pressure of carbon dioxide; HCO3, bicarbonate. Values represent mean standard error. SHAM (n¼ 5), CONTROL (n¼ 5), ATL
(n ¼ 5). aP< .001 versus CONTROL and ATL. bP< .05 versus CONTROL and ATL.rdiovascular Surgery c Volume 136, Number 5 1283
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PTABLE 3. Cytokine analysis
Lung tissue (pg/mL)
IL-1 IL-6 TNF-a IFN-g
SHAM 10,865  1086 403  88 811  90 1870  9
CONTROL 22,839  536a 7402  371b 2002  148b 2530  9c
ATL 21,033  694a 2136  247 765  129 1770  20
BAL (pg/mL)
IL-1 IL-6 TNF-a IFN-g
SHAM 382  45 126  41 311  24 75  17
CONTROL 753  45b 389  70b 330  10 161  17b
ATL 434  45 178  12 285  43 52  7
Plasma (pg/mL)
IL-1 IL-6 TNF-a IFN-g
SHAM 243  13 91  5 193  14 92  10d
CONTROL 249  16 102  9 169  4 124  4
ATL 225  6 89  3 165  8 124  8
IL, Interleukin; TNF, tumor necrosis factor; IFN, interferon; BAL, bronchoalveolar lavage. Values represent mean standard error. SHAM (n¼ 5), CONTROL (n¼ 5), ATL (n¼
5). aP< .001 versus SHAM. bP< .001 versus SHAM and ATL. cP< .05 versus SHAM and ATL. dP< .05 versus CONTROL and ATL.elevations in IL-1, IL-6, and IFN-g compared with SHAM.
The addition of ATL313 to the bypass prime (ATL group)
significantly reduced the expression of IL-1, IL-6, and
IFN-g back to SHAM levels. There were no differences
noted in the levels of TNF-a within the BAL fluid for the
3 groups. The levels of IL-1, IL-6, TNF-a, and IFN-g in
the plasma were comparatively low and found to be similar
among the 3 groups.
Myeloperoxidase Levels
MPO levels within the BAL fluid were used as an indica-
tor of neutrophil activation and sequestration into alveolar
airspace (Figure 2). The CONTROL group was found to
have significant elevations in MPO level relative to
SHAM. The addition of ATL313 to the standard bypass
prime (ATL group) led to a 59% reduction in MPO activity
compared with the CONTROL group (P<.05). There were
no significant differences in MPO activity observed between
the ATL group and the SHAM group.
Wet/Dry Weight Ratio Analysis
Wet-to-dry weight ratios were analyzed as an indicator of
pulmonary edema (Figure 3). The CONTROL group was
found to have a significantly higher wet-to-dry weight ratio
compared with SHAM. The addition of ATL313 to the stan-
dard bypass prime (ATL group) resulted in a 63% reduction
in wet/dry weight ratio compared with the CONTROL group
(P<.001). There were no significant differences in the wet/
dry ratios observed between the ATL group and the SHAM
group.
Lung Injury Severity
The CONTROL group had considerably more lung injury
relative to SHAM. The addition of ATL313 to the bypass
prime resulted in significant improvements in lung histology1284 The Journal of Thoracic and Cardiovascular S(Figure 4) and lung injury severity score (Table 4) compared
with the CONTROL group (P<.001 for overall lung injury
severity score). Lung histology and lung injury severity were
similar between the ATL group and the SHAM group.
DISCUSSION
This study demonstrates that A2AR activation during CPB
results in a significant reduction in the pulmonary inflamma-
tory response observed after CPB in a rat model. The addi-
tion of ATL313 to the standard bypass prime, before the
initiation of CPB, resulted in significantly decreased levels
of the potent proinflammatory cytokines, IL-1, IL-6, TNF-
a, and IFN-g in BAL fluid and lung tissue, and resulted in
decreased neutrophil sequestration and activation (decreased
BALMPO level), decreased pulmonary edema, less lung in-
jury, and preserved lung histology. Presumably, these im-
provements in quantitative inflammatory markers may
translate into improved physiology after CPB, although
the true effects on lung physiology were not evaluated in
this study.
Cardiac surgery using CPB is a well-known trigger of
a substantial inflammatory response in both humans after
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FIGURE 2. BAL MPO. SHAM (n ¼ 5), CONTROL (n ¼ 5), ATL (n ¼
5). *P< .05 versus sham and ATL. MPO, Myeloperoxidase.urgery c November 2008
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Proutine CPB and in animal models of CPB.2,4,13-16 This
inflammatory response can in turn lead to dysfunction in
several organ systems, including the cardiovascular,
pulmonary, renal, hepatic, gastrointestinal, hematopoietic,
and central nervous systems.2 This dysfunction can range
in severity from mild organ dysfunction to severe life-threat-
ening multiorgan failure. Several mechanisms have been
shown to contribute to the inflammatory response during
CPB, including direct surgical trauma, ischemia-reperfusion
injury, exposure of blood to the foreign surfaces of the CPB
circuit, direct release of endotoxin, and changes in body tem-
perature.2,4 We hypothesize that 2 important mechanisms
play a role in the inflammatory response within the lung after
CPB in our model: exposure of blood to the foreign CPB cir-
cuit and pulmonary ischemia-reperfusion injury.
An important source of inflammatory cell activation in our
model is from the interaction of the blood with foreign sur-
faces of the CPB circuit. Despite improvements in the com-
position of the internal lining of the circuit, the addition of
heparin-coated circuits, leukocyte depletion filters, and ul-
trafiltration techniques, ample evidence exists describing
the persistent activation of complement, coagulation, fibri-
nolytic, and inflammatory responses during CPB.2,4 Strong
evidence suggests that the end result of these processes is
the sequestration and activation of macrophages, eosino-
phils, neutrophils, mast cells, platelets, endothelial cells,
and T lymphocytes.
Another important source of inflammatory activation dur-
ing CPB may be the result of lung ischemia-reperfusion in-
jury. Because perfusion of the lungs during CPB is limited
predominantly to flow received from the bronchial arteries,
ischemic injury to the lungs during CPB is a likely conse-
quence, despite seemingly adequate systemic perfusion by
the CPB pump. Several studies have demonstrated this in
various models of CPB. By using a pig model of CPB,
Schlensak and collegues17 demonstrated a significant de-
cline in bronchial artery blood flow with the onset of CPB,
which led to lung inflammatory activation and subsequent
injury. They were able to eloquently show that lung injury
and inflammation were markedly reduced with controlled
pulmonary artery perfusion during CPB. Similar results
have been described by others, in both human and animal
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FIGURE 3. Wet/dry analysis. SHAM (n ¼ 5), CONTROL (n ¼ 5), ATL
(n ¼ 5). *P< .001 versus SHAM and ATL.The Journal of Thoracic and CaFIGURE 4. Representative hematoxylin-eosin sections of lung tissue. A,
SHAM group: Normal-appearing pneumocytes apposed to capillaries are
observed, without evidence of inflammatory infiltrate, alveolar macro-
phages, or edema. B, CONTROL group: Alveolar septa are substantially
widened, and there are multiple alveolar macrophages and significant
edema. C, ATL group: Alveolar septa are minimally widened by interstitial
infiltrate, very few alveolar macrophages are observed, and there is sparse
edema.rdiovascular Surgery c Volume 136, Number 5 1285
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PTABLE 4. Lung injury severity scoring
Group Interstitial infiltrate Macrophages Alveolar edema Total score
SHAM 0.2  0.17 0.0  0.0 0.0  0.0 0.2  0.17
CONTROL 0.6  0.21a 1.6  0.43a 2.1  0.21a 4.3  0.41b
ATL 0.3  0.21 0.4  0.21 0.1  0.14 0.8  0.17
Values represent mean scores  standard error. SHAM (n ¼ 5), CONTROL (n ¼ 5), ATL (n ¼ 5). aP< .05 versus SHAM and ATL. bP< .001 versus SHAM and ATL.models of CPB.18,19 Although we did not directly measure
the influence of bronchial artery blood flow in the present
study, our results indicate a robust pulmonary inflammatory
response after the bypass period with significant elevations
in IL-1, IL-6, TNF-a, IFN-g, MPO, pulmonary edema,
and lung parenchymal injury. There was a relative lack of in-
flammatory activation, as measured by a lack of induction of
proinflammatory cytokines, in the plasma, which is in con-
trast with the results of other investigators. One possible ex-
planation is that our post-bypass recovery time (90 minutes)
was not long enough to demonstrate the propagation of sys-
temic inflammation within the plasma.
Adenosine is a primitive signaling molecule that serves to
modulate several physiologic responses in the majority of
mammalian tissues.20 More specifically, it has significant
anti-inflammatory properties and has been shown to exert
a protective role against the development of ischemia-in-
duced cell injury.6-9,20-22 Specific activation of the A2AR
subtype has been shown to be protective against the develop-
ment of lung ischemia-reperfusion injury.6,9,23 Previous in-
stitutional research has indicated that the activation of the
A2AR is mediated specifically by ATL313.
6 Although the
global understanding of A2AR agonists and their influences
on lung ischemia-reperfusion injury are largely known, the
exact mechanisms by which A2AR activation attenuates
the inflammatory response induced by CPB have not been
well described. Presumably, the action of ATL313 in limit-
ing the inflammatory response after CPB is similar to the
mechanism by which A2AR agonism attenuates ischemia-re-
perfusion injury in other organ systems. There is extensive,
well-supported evidence for the role of inflammatory cells in
the propagation of the CPB-induced inflammation. A2ARs
have been shown to be present on nearly all inflammatory
cells, including macrophages, eosinophils, neutrophils,
mast cells, platelets, endothelial cells, and T lymphocytes,
and subsequent activation of the A2AR has been shown to
be almost uniformly inhibitory in these cell lines.20,24 Fur-
thermore, A2AR agonists have been shown to decrease the
expression of several adhesion molecules, including inter-
cellular adhesion molecule-1, P-selectin, and vascular cell
adhesion molecule-1 in myocardial and renal ischemia-re-
perfusion models.19,21 Many of these same adhesion mole-
cules have been shown to have important effects in the
propagation of CPB-induced inflammation.25 Therefore,
the observed anti-inflammatory activity of ATL313 in our
CPB model could involve 2 important mechanisms. First,1286 The Journal of Thoracic and Cardiovascular SATL313 could attenuate the inflammatory response gener-
ated by the foreign surfaces of the CPB circuit itself, and sec-
ond, it could reduce the inflammatory response associated
with the relative pulmonary ischemia that occurs during
CPB.
CONCLUSIONS
This report demonstrates that the addition of a potent
A2AR agonist to the normal priming solution before the ini-
tiation of CPB significantly protects the lung from the inflam-
matory effects of CPB and reduces the amount of lung injury.
The ability to adequately protect the lung and other organs
from ischemia-reperfusion injury and attenuate the activa-
tion of an inflammatory response by the CPB circuit itself
suggest that A2AR agonists may represent a new therapeutic
strategy for reducing the potentially devastating conse-
quences of the inflammatory response associated with CPB.
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Discussion
Dr Frank Sellke (Boston, Mass). Is there a physiologic correlate
to this or is this purely a pharmacologic manifestation?
Dr Lisle. At this point it is purely a pharmacologic manifesta-
tion, in that we don’t see many physiologic changes when we
give the drug. If we give it in a very high dose, it causes substantial
vasodilation and hypotension. The dose that we give has been pre-
viously tested in our laboratory and found to be the most effective
dose without the aforementioned side effects. We were unable to
measure pulmonary artery pressure in the rats, which is something
that we are currently working on.
Dr Sellke. You found a tremendous benefit to this drug. Is there
some cellular mechanism that would explain all these different find-
ings simultaneously?
Dr Lisle. ATL313 is a specific A2AR agonist that belongs to
a family of adenosine receptors (A1, A2A, A2B, and A3) that are
ubiquitous throughout most tissues and most specific to inflamma-
tory cells, endothelial cells, macrophages, T cells, and neutrophils,
and it is shown to be uniformly inhibitory in those cell lines. So it is
something that we have been able to show before, but never in this
model.
Dr Paul Kurlansky (Miami, Fla). I just wanted to pursue that
exact line of thought, because what you havemeasured is obviouslyThe Journal of Thoracic and Cadownstream from the impact that this receptor is having. I was won-
dering if you could give us a little bit of guidance as to exactly
where in the inflammatory cascade this receptor is acting. Is this be-
fore nuclear factor kappa beta? You have complement release vir-
tually immediately, and yet the downstream effect seems to be
ameliorated in several different areas. So I was wondering if you
could just mechanistically give us sort of a tour of where you think
this is working?
Dr Lisle. I think it is probably working in concert with a few dif-
ferent cell lines at a few different points in the inflammatory path-
way. Our laboratory has done somework that you will hear about in
a little while, so I don’t want to necessarily spoil the punch line, but
I think it certainly works on a whole host of those cell lines. I think
that there is a substantial inflammatory activation within the bypass
pump itself. I also think there is a marked reperfusion injury within
the lung after bypass, and my guess is that the drug is helping atten-
uate both of those inflammatory responses.
Dr Christopher Caldarone (Toronto, Ontario, Canada). The
slides went by kind of quick, but I think you said that there weren’t
any changes in terms of oxygenation and physiologic parameters of
the lung, which weakens your argument a little bit that these
changes are clinically relevant. Nevertheless, your data are impres-
sive. What plans do you have in terms of what you are going to do
with your model to perhaps change it so you could demonstrate
clinically relevant changes in the model?
It really is an elegant model, and for those of us who might con-
template setting up a rat bypass model, what was your learning
curve like and how technically difficult is it to get one of these stud-
ies to go from start to finish?
Dr Lisle. This study is a compilation of about 2 years’ worth of
work for me in Dr Kron’s laboratory. The learning curve was sub-
stantially steep, but once you master it, things seem to become a lot
easier; at least I’d like to think so.
Dr Caldarone. I think that is the case with all science.
Dr Lisle. To answer your second question, the majority of the
animals we bypass go on to survive. Postoperatively, they are ex-
traordinarily hard to keep alive, and they require intense care
once they are extubated. We don’t see a lot of changes in oxygen-
ation initially, but my guess is that if we took them out further, more
than 90 minutes, we would see more significant changes in terms of
oxygenation and so forth. The direction we are heading right now is
to look at the effects of ventilation during bypass and then see if we
can figure out how this inflammatory response fits into the picture
of ischemia-reperfusion injury with other organ systems. The hy-
pothesis that we are going on now is that the lung is the centerpiece
of this whole inflammatory cascade within the body, resulting in
a systemic inflammatory response syndrome because it is relatively
ischemic with the cessation of pulmonary artery blood flow relative
to the rest of the organs in the body.
Dr William Smythe (Temple, Tex). We have a surgeon in my
department that has been working for the last several years on gen-
eralized endothelial or microvascular dysfunction in shock states.
As you know, that is a whole body ischemia-reperfusion model
whereby animals either have septic or hemorrhagic shock, and there
is a generalized microvascular permeability issue. This process can
involve extrathoracic sites, such as the brain, kidneys, and other tis-
sues or organs, many of which have deleterious effects on patients
in the intensive care unit and may lead to patient morbidity andrdiovascular Surgery c Volume 136, Number 5 1287
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Pmortality. Do you have any evidence that ATL313 works on micro-
vascular permeability states in other areas of the body besides the
lung specifically?
DrLisle.There certainly has been a host of literature published on
the subject with ATL313 and its effects on adhesion molecules like
P-selectin, for example.We haven’t been able to evaluate any of that
specifically, but it is certainly somewhere we could go in the future.
Dr Yoshiya Toyoda (Pittsburgh, Pa). In your program do you
use adenosine during lung transplantation or CPB, and if so,
how? Do you put it in the pump prime or give it directly to the lung?1288 The Journal of Thoracic and Cardiovascular SuDr Lisle.We haven’t started using adenosine or ATL clinically
at the University of Virginia for lung transplantation; however, it is
being studied presently in a phase III trial for cardiac imaging. I ex-
pect, coming down the pipeline within the next 12 months or so, we
will start to see a compound similar to ATL313 in phase II trials for
acute inflammation, but nothing at this point.
Dr Toyoda. At the University of Pittsburgh Medical Center, we
have been using adenosine clinically since 1997 or so. We admin-
ister it directly into the lung through the pulmonary artery with
good outcome against ischemia-reperfusion injury.rgery c November 2008
